Profile data is unavailable for this security.
About the company
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
- Revenue in USD (TTM)863.49m
- Net income in USD-188.86m
- Incorporated1991
- Employees3.93k
- LocationOPKO Health Inc4400 Biscayne Blvd.MIAMI 33137United StatesUSA
- Phone+1 (305) 575-4181
- Websitehttps://www.opko.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | 314.00k | -237.73m | 797.15m | 96.00 | -- | 2.91 | -- | 2,538.69 | -5.32 | -5.32 | 0.007 | 8.19 | 0.0007 | -- | 3.08 | 3,340.43 | -51.37 | -55.59 | -54.93 | -60.32 | -- | -- | -75,711.47 | -5,678.12 | -- | -- | 0.0437 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| National Research Corporation | 148.58m | 30.96m | 801.85m | 435.00 | 26.75 | 16.62 | 21.75 | 5.40 | 1.26 | 1.26 | 6.02 | 2.02 | 1.18 | -- | 11.00 | 341,563.20 | 24.49 | 26.25 | 33.80 | 36.77 | 62.30 | 63.20 | 20.84 | 23.95 | -- | 1,929.64 | 0.4286 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| Eyepoint Pharmaceuticals Inc | 46.02m | -70.80m | 805.27m | 121.00 | -- | 2.98 | -- | 17.50 | -1.84 | -1.84 | 1.18 | 5.43 | 0.1719 | 1.36 | 5.64 | 380,314.10 | -26.44 | -40.44 | -32.35 | -47.79 | 89.93 | 83.45 | -153.84 | -186.23 | 5.39 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Relay Therapeutics Inc | 25.55m | -341.97m | 807.41m | 323.00 | -- | 1.04 | -- | 31.61 | -2.79 | -2.79 | 0.2095 | 5.90 | 0.0263 | -- | 9.79 | 79,089.78 | -35.19 | -28.55 | -36.97 | -29.54 | -- | -- | -1,338.66 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 816.25m | 487.00 | -- | 1.16 | -- | 8.96 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Cullinan Therapeutics Inc | 0.00 | -153.16m | 829.01m | 85.00 | -- | 1.82 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| USANA Health Sciences, Inc. | 921.01m | 63.79m | 830.04m | 1.80k | 13.08 | 1.66 | 10.85 | 0.9012 | 3.30 | 3.30 | 47.61 | 25.99 | 1.50 | 2.75 | -- | 511,672.20 | 10.38 | 16.23 | 13.20 | 21.75 | 80.82 | 81.42 | 6.93 | 8.96 | 3.00 | -- | 0.0016 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| OPKO Health Inc | 863.49m | -188.86m | 850.33m | 3.93k | -- | 0.6791 | -- | 0.9848 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| Immunome Inc | 14.02m | -106.81m | 851.24m | 55.00 | -- | 5.14 | -- | 60.72 | -3.33 | -3.33 | 0.7064 | 2.77 | 0.1625 | -- | -- | 254,872.70 | -123.77 | -94.54 | -148.94 | -112.66 | -- | -- | -761.92 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| SS Innovations International Inc | 5.88m | -20.94m | 851.91m | 239.00 | -- | 59.58 | -- | 144.89 | -0.1293 | -0.1293 | 0.04 | 0.0838 | 0.3939 | -- | 2.53 | 24,601.30 | -140.31 | -161.38 | -253.40 | -449.76 | 12.13 | -79.79 | -356.17 | -495.77 | 1.30 | -52.51 | 0.2963 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| ALX Oncology Holdings Inc | 0.00 | -160.81m | 851.92m | 72.00 | -- | 4.44 | -- | -- | -3.74 | -3.74 | 0.00 | 3.80 | 0.00 | -- | -- | 0.00 | -58.58 | -34.34 | -66.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0592 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Bicycle Therapeutics PLC (ADR) | 26.98m | -180.66m | 855.02m | 284.00 | -- | 2.58 | -- | 31.70 | -5.13 | -5.13 | 0.7585 | 8.74 | 0.0536 | -- | 26.38 | 94,985.91 | -35.92 | -29.45 | -40.92 | -32.98 | -- | -- | -669.72 | -571.36 | -- | -- | 0.0764 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| BioCryst Pharmaceuticals Inc | 331.41m | -226.54m | 857.58m | 536.00 | -- | -- | -- | 2.59 | -1.18 | -1.18 | 1.72 | -2.21 | 0.6212 | 0.1658 | 6.16 | 618,306.00 | -42.46 | -47.95 | -55.84 | -64.89 | 98.59 | 97.06 | -68.36 | -114.94 | 3.12 | -1.11 | 2.19 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Praxis Precision Medicines Inc | 2.45m | -123.28m | 875.53m | 82.00 | -- | 6.67 | -- | 357.80 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| MacroGenics Inc | 58.75m | -9.06m | 898.99m | 339.00 | -- | 5.84 | 1,534.12 | 15.30 | -0.1525 | -0.1525 | 0.9462 | 2.46 | 0.203 | 6.15 | 1.76 | 173,300.90 | -3.13 | -37.76 | -3.82 | -45.53 | 86.00 | -- | -15.42 | -133.96 | 4.46 | -117.57 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
Data as of Apr 26 2024. Currency figures normalised to OPKO Health Inc's reporting currency: US Dollar USD
18.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 39.06m | 5.60% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 31.94m | 4.58% |
| Geode Capital Management LLCas of 31 Dec 2023 | 9.72m | 1.39% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 9.31m | 1.34% |
| KSM Mutual Funds Ltd.as of 31 Jan 2024 | 9.30m | 1.33% |
| Migdal Mutual Funds Ltd.as of 31 Jan 2024 | 6.12m | 0.88% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 5.84m | 0.84% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 5.73m | 0.82% |
| Invesco Capital Management LLCas of 31 Dec 2023 | 5.48m | 0.79% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 4.80m | 0.69% |
More ▼
Data from 31 Dec 2023 - 31 Jan 2024Source: FactSet Research Systems Inc.
